{"id":"W4290994344","doi":"10.1200/jco.22.00597","title":"Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"ca_institutions":"Spinal Cord Injury BC","funders":"Janssen Biotech; National Cancer Institute; University of Texas MD Anderson Cancer Center; National Institutes of Health; Genentech; Janssen Scientific Affairs; Karyopharm Therapeutics; Conquer Cancer Foundation; Gilead Sciences; Sanofi; MorphoSys; Celgene; AstraZeneca; Bristol-Myers Squibb; American Society of Clinical Oncology; GlaxoSmithKline; Amgen","keywords":"Medicine; Lenalidomide; Ibrutinib; Rituximab; Chemoimmunotherapy; Internal medicine; Chemotherapy; Diffuse large B-cell lymphoma; Oncology; International Prognostic Index; Surgery; Lymphoma; Gastroenterology; Multiple myeloma; Leukemia; Chronic lymphocytic leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008808114,0.0003905339,0.001126149,0.0002793968,0.000197129,0.0005189983,0.0003162638,0.0004056784,0.001292286],"category_scores_gemma":[0.0007246276,0.0002783914,0.0004151153,0.0002803446,0.0002863726,0.000449867,0.0004736159,0.0008780714,0.0003332807],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000479747,"about_ca_system_score_gemma":0.0007124008,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004276843,"about_ca_topic_score_gemma":0.001992936,"domain_scores_codex":[0.9996679,0.0001384444,0.00003139965,0.00005824296,0.00005544565,0.00004867036],"domain_scores_gemma":[0.9995561,0.00009026559,0.0001060883,0.00001526665,0.00002098651,0.0002113192],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.297614,0.008813419,0.346523,0.001120418,0.001073199,0.0009704557,0.0003705872,0.003354306,0.0261387,0.0003856061,0.01050178,0.3031345],"study_design_scores_gemma":[0.1432966,0.2290993,0.5747998,0.0003245787,0.002030225,0.002377078,0.0003692318,0.008424271,0.008526944,0.0006121357,0.03002431,0.0001155101],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9898338,0.005833286,0.00027843,0.0004319303,0.0001083171,0.0004218443,0.0006015709,0.0000539349,0.002436856],"genre_scores_gemma":[0.9947861,0.001674567,0.0008196683,0.0007100874,0.00010439,0.0003450867,0.0008414903,0.000006073265,0.0007124839],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001292286,"threshold_uncertainty_score":0.004658222,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04737117210037393,"score_gpt":0.3881505520512346,"score_spread":0.3407793799508607,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}